Seaward Management Limited Partnership Has $11.04 Million Position in Becton, Dickinson and Company (BDX)

Seaward Management Limited Partnership lowered its holdings in Becton, Dickinson and Company (NYSE:BDX) by 3.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,336 shares of the medical instruments supplier’s stock after selling 2,209 shares during the quarter. Seaward Management Limited Partnership’s holdings in Becton, Dickinson and were worth $11,039,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of BDX. Advantus Capital Management Inc increased its stake in Becton, Dickinson and by 0.7% in the first quarter. Advantus Capital Management Inc now owns 21,513 shares of the medical instruments supplier’s stock valued at $3,946,000 after acquiring an additional 144 shares during the period. Homrich & Berg grew its stake in Becton, Dickinson and by 3.6% during the first quarter. Homrich & Berg now owns 3,532 shares of the medical instruments supplier’s stock worth $648,000 after buying an additional 122 shares during the last quarter. Teachers Advisors LLC grew its stake in Becton, Dickinson and by 4.0% during the first quarter. Teachers Advisors LLC now owns 360,409 shares of the medical instruments supplier’s stock worth $66,113,000 after buying an additional 13,836 shares during the last quarter. Boston Financial Mangement LLC grew its stake in Becton, Dickinson and by 10.2% during the first quarter. Boston Financial Mangement LLC now owns 55,702 shares of the medical instruments supplier’s stock worth $10,218,000 after buying an additional 5,152 shares during the last quarter. Finally, Stephens Inc. AR grew its stake in Becton, Dickinson and by 9.8% during the first quarter. Stephens Inc. AR now owns 11,391 shares of the medical instruments supplier’s stock worth $2,089,000 after buying an additional 1,016 shares during the last quarter. 87.91% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company (BDX) traded down $1.21 on Monday, hitting $220.31. 719,600 shares of the stock traded hands, compared to its average volume of 1,325,275. Becton, Dickinson and Company has a twelve month low of $161.29 and a twelve month high of $225.23. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01. The company has a market capitalization of $50,130.00, a PE ratio of 23.22, a P/E/G ratio of 1.73 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. During the same period in the prior year, the firm earned $2.12 earnings per share. Becton, Dickinson and’s revenue was down 2.0% compared to the same quarter last year. sell-side analysts anticipate that Becton, Dickinson and Company will post 10.63 EPS for the current fiscal year.

Several analysts have weighed in on BDX shares. BidaskClub cut shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Barclays PLC reaffirmed an “equal weight” rating and set a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Finally, Cowen and Company reaffirmed a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a research note on Monday, August 14th. Five research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $214.79.

COPYRIGHT VIOLATION WARNING: “Seaward Management Limited Partnership Has $11.04 Million Position in Becton, Dickinson and Company (BDX)” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://ledgergazette.com/2017/11/20/seaward-management-limited-partnership-has-11-04-million-position-in-becton-dickinson-and-company-bdx.html.

In related news, insider Stephen Sichak sold 11,787 shares of the stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $200.46, for a total value of $2,362,822.02. Following the transaction, the insider now directly owns 14,038 shares in the company, valued at $2,814,057.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Linda M. Tharby sold 4,695 shares of the stock in a transaction that occurred on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total transaction of $941,253.60. Following the completion of the transaction, the executive vice president now owns 18,670 shares in the company, valued at $3,742,961.60. The disclosure for this sale can be found here. Insiders sold 47,038 shares of company stock worth $9,480,225 over the last 90 days. 1.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply